ALLMedicine™ Folliculitis Center

Mar 14th, 2023 - Malassezia is a lipophilic yeast that is a part of the human mycobiome. Malassezia folliculitis appears when the benign colonization of the hair follicles, by the Malassezia yeasts, becomes symptomatic with pruritic papules and pustules. Although ...

Mar 11th, 2023 - The risk factors for skin injuries remain poorly understood in cancer patients with peripherally inserted central catheters (PICC). We herein aimed at exploring the effect of clinical factors on the risk of PICC-related skin injuries. We included ...

Mar 2nd, 2023 - Eosinophilic pustular folliculitis in infancy: a rare disease|2023|Ashworth J,Nogueira M,Freitas E,Ferreira L,Tente D,|

Feb 24th, 2023 - Tufted Hair Folliculitis: Doll's Hair.|2023|Zhang LW,Chen T,|

Feb 23rd, 2023 - There has been no validated tool for objectively quantifying the overall condition and characteristics of the scalp. This study aimed to establish and validate a new classification and scoring system for evaluating scalp conditions. The Scalp Phot...

Nov 8th, 2022 - Acne keloidalis nuchae (AKN) is one of the chronic forms of scarring folliculitis, affecting predominantly the occipital scalp, seen mostly in men of African descent. Duobrii has the advantage of being the only high potency topical steroid-retinoi...

Sep 22nd, 2022 - Malassezia folliculitis is a common disease of young and middle-aged people. It is an inflammatory disease caused by Malassezia infection. Generally, Topical or systemic use of antifungal drugs are the first choice for treatment but sometimes are ...

May 2nd, 2022 - Ialuxid® Gel is a non-antibiotic treatment in gel indicated for use in a variety of skin conditions, and also in case of infection. Its principal ingredient is Ialuvance™ Complex, a proprietary association of hydrogen peroxide, hyaluronic acid, an...

Apr 6th, 2022 - Eye infection is a prevalent problem in primary care and remains a crucial healthcare concern. According to the American Academy of Ophthalmology (AAO), herpes simplex virus (HSV) keratitis (HSK) is the leading cause of infectious blindness worldw...

Dec 14th, 2021 - The first-line drug treatment for mild-moderate AD are currently topical corticosteroids (TCS) with recognized efficacy. However, their prolonged or inappropriate use, can lead to local adverse effects. Side-effects of topical corticosteroids comp...

Jan 31st, 2023 - New treatments for psoriasis constitute an embarrassment of riches compared to any other area of dermatology. Despite the many advances over the last 25 years, additional topical and systemic treatments have recently become available.

Dec 1st, 2022 - Many patients with hidradenitis suppurativa (HS) return to emergency departments – not to dermatology clinics – for their ongoing care, according to a study of a large national administrative data set. “Patients with HS presenting to the ED for th.

Dec 1st, 2022 - Many patients with hidradenitis suppurativa (HS) return to emergency departments – not to dermatology clinics – for their ongoing care, according to a study of a large national administrative data set. “Patients with HS presenting to the ED for th...

Sep 11th, 2022 - The FDA approved the first-in-class oral tyrosine kinase 2 (TYK2) inhibitor deucravacitinib (Sotyktu) for moderate-to-severe plaque psoriasis, Bristol Myers Squibb announced. The indication limits use to adults who are candidates for systemic ther...

Jun 13th, 2022 - The FDA approved the Janus kinase (JAK) inhibitor baricitinib (Olumiant) as the first systemic treatment for alopecia areata. The approval pertains to adults with severe alopecia areata, which affects more than 300,000 people in the U.S. each year...